All lobbying filings

TERUMO BCT, INC.

Lobbying for TERUMO BCT, INC. · Medical technology company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Colorado · House · Senate · $20,000.00 expenses · posted Aug 7, 2026

Official filing document

Bills named in this filing 2

S 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Lobbying activity 3

Trade (domestic/foreign)

Global trade and tariffs

Health Issues

S.735/H.R. 1796 - Reauthorization of Sickle Cell Disease and Other Heritable Blood Disorders Research, Blood and cell collection, storage, and processing Blood donation supply and quality

Medicare/Medicaid

Medicaid Eligibility, work and community engagement requirements

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.